Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Leads from the MMWR

Leads from the MMWR from the Leads MMWR and Weekly 32/No. Centers for Disease Atlanta Morbidity Mortality Report (Vol. 52, 1983), Control, infection. At the fever can Yellow Fever Vaccine present time, jungle yellow be in most humans immuni¬ effectively prevented by revised Immunization Practices zation. These Advisory Committee recommendations fever vaccine on yellow the recommendations update previous (MMWR Yellow Fever Vaccine: have been made to 1978:27:268-270). Changes clarify the risks of fever associated with vaccine a attenuated virus (1) acquiring yellow Yellow fever is live, travel endemic the to made from 17D fever virus (2) the areas; precautions necessary preparation yellow for immunization infants strain. The 17D vaccine has be of and to special groups (eg, proven extremely for of and effective. The strain is in immunization safe 17D chick pregnant women); (3) procedures grown with histories of and seed inoculated with a virus of a fixed- persons possible egg allergy; (4) embryo level. simultaneous administration of other vaccines. The vaccine is of freeze-dried passage supernate in one- centrifuged embryo homogenate, packaged and five-dose for Introduction: dose vials domestic use. Vaccine should be between stored at temperatures occurs in °C and °C Yellow fever Africa and 5 -30 presently only (41 °F) http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Leads from the MMWR

JAMA , Volume 251 (4) – Jan 27, 1984

Loading next page...
 
/lp/american-medical-association/leads-from-the-mmwr-0QmwhN7ZjM
Publisher
American Medical Association
Copyright
Copyright © 1984 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.1984.03340280010004
Publisher site
See Article on Publisher Site

Abstract

from the Leads MMWR and Weekly 32/No. Centers for Disease Atlanta Morbidity Mortality Report (Vol. 52, 1983), Control, infection. At the fever can Yellow Fever Vaccine present time, jungle yellow be in most humans immuni¬ effectively prevented by revised Immunization Practices zation. These Advisory Committee recommendations fever vaccine on yellow the recommendations update previous (MMWR Yellow Fever Vaccine: have been made to 1978:27:268-270). Changes clarify the risks of fever associated with vaccine a attenuated virus (1) acquiring yellow Yellow fever is live, travel endemic the to made from 17D fever virus (2) the areas; precautions necessary preparation yellow for immunization infants strain. The 17D vaccine has be of and to special groups (eg, proven extremely for of and effective. The strain is in immunization safe 17D chick pregnant women); (3) procedures grown with histories of and seed inoculated with a virus of a fixed- persons possible egg allergy; (4) embryo level. simultaneous administration of other vaccines. The vaccine is of freeze-dried passage supernate in one- centrifuged embryo homogenate, packaged and five-dose for Introduction: dose vials domestic use. Vaccine should be between stored at temperatures occurs in °C and °C Yellow fever Africa and 5 -30 presently only (41 °F)

Journal

JAMAAmerican Medical Association

Published: Jan 27, 1984

There are no references for this article.